Fmr LLC Boosts Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Fmr LLC grew its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 0.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,292,881 shares of the company’s stock after buying an additional 9,115 shares during the quarter. Fmr LLC owned 14.93% of Krystal Biotech worth $781,433,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Key Financial Inc purchased a new position in Krystal Biotech during the second quarter worth about $28,000. GAMMA Investing LLC lifted its holdings in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after acquiring an additional 93 shares during the period. Jamison Private Wealth Management Inc. acquired a new stake in Krystal Biotech in the second quarter valued at $28,000. Blue Trust Inc. lifted its holdings in Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after acquiring an additional 163 shares during the period. Finally, Values First Advisors Inc. acquired a new stake in Krystal Biotech in the third quarter valued at $53,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Trading Up 0.2 %

Krystal Biotech stock opened at $196.91 on Thursday. The stock has a market cap of $5.66 billion, a PE ratio of 111.25 and a beta of 0.82. The stock has a 50-day moving average price of $179.98 and a 200 day moving average price of $183.19. Krystal Biotech, Inc. has a 52 week low of $99.00 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.67) EPS. On average, equities analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Analysts Set New Price Targets

KRYS has been the subject of a number of recent analyst reports. William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Evercore ISI raised their price target on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research report on Tuesday, November 5th. Citigroup raised their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Chardan Capital raised their price target on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech currently has an average rating of “Buy” and a consensus target price of $202.29.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 1.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 14.10% of the stock is owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).